Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice
- 15 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 194 (4) , 1695-1701
Abstract
Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing Ab responses. Ninety percent of patients with normal immune systems make neutralizing Abs after one cycle of RIT, preventing repeated dosing. Furthermore, some patients have pre-existing Abs from environmental exposure to Pseudomonas exotoxin, the component of the RIT that elicits the neutralizing Ab response. Bortezomib is an U.S. Food and Drug Administration–approved proteasome inhibitor that selectively targets and kills plasma cells that are necessary for the neutralizing Ab response. We hypothesized that bortezomib may abrogate neutralizing Ab levels, making dosing of RIT possible in mice already immune to RIT. We immunized BALB/c mice with multiple doses of SS1P, a RIT whose Ab portion targets mesothelin. Mice with elevated Ab levels were separated into groups to receive saline, bortezomib, the pentostatin/cyclophosphamide (PC) regimen, or the bortezomib/PC (BPC) combination regimen. Four weeks after finishing therapy, plasma Ab levels were assayed, and bone marrow was harvested. The bortezomib and PC regimens significantly reduced Ab levels, and we observed fewer plasma cells in the bone marrow of bortezomib-treated mice but not in PC-treated mice. The BPC combination regimen almost completely eliminated Abs and further reduced plasma cells in the bone marrow. This regimen is more effective than individual regimens and may reduce Ab levels in patients with pre-existing neutralizing Abs to Pseudomonas exotoxin, allowing RIT treatment.Keywords
This publication has 32 references indexed in Scilit:
- Immunotoxins for leukemiaBlood, 2014
- Immunotoxins: The Role of the ToxinToxins, 2013
- Proteasome Inhibition Profoundly Affects Activated Human B CellsTransplantation, 2013
- A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced AntigenicityMolecular Cancer Therapeutics, 2013
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2012
- A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicityProtein Engineering, Design and Selection, 2011
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences, 2011
- Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome InhibitionCancer Research, 2007
- Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer PatientsThe Journal of Immunology, 2006
- Competence and competition: the challenge of becoming a long-lived plasma cellNature Reviews Immunology, 2006